New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - nadolol 80mg;  ;   - tablet - 80 mg - active: nadolol 80mg     excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - prophylaxis of angina pectoris

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - nadolol (unii: fen504330v) (nadolol - unii:fen504330v) - nadolol 20 mg - nadolol tablets usp are indicated for the long-term management of patients with angina pectoris. nadolol tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nadolol tablets usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pres

Canada - English - Health Canada

mint pharmaceuticals inc - nadolol - tablet - 80mg - nadolol 80mg - beta-adrenergic blocking agents

Canada - English - Health Canada

apotex inc - nadolol - tablet - 80mg - nadolol 80mg - beta-adrenergic blocking agents

Canada - English - Health Canada

teva canada limited - nadolol - tablet - 80mg - nadolol 80mg - beta-adrenergic blocking agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - nadolol - oral tablet - 80mg

United States - English - NLM (National Library of Medicine)

sandoz inc - nadolol (unii: fen504330v) (nadolol - unii:fen504330v) - nadolol 20 mg - nadolol tablets usp are indicated for the long-term management of patients with angina pectoris. nadolol tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nadolol tablets usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pres

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - nadolol (unii: fen504330v) (nadolol - unii:fen504330v) - nadolol 20 mg - nadolol tablets are indicated for the long-term management of patients with angina pectoris. nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nadolol tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure educati

United States - English - NLM (National Library of Medicine)

impax generics - nadolol (unii: fen504330v) (nadolol - unii:fen504330v), bendroflumethiazide (unii: 5q52x6icji) (bendroflumethiazide - unii:5q52x6icji) - nadolol 40 mg - nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on pr

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - nadolol (unii: fen504330v) (nadolol - unii:fen504330v) - nadolol 20 mg - nadolol tablets are indicated for the long-term management of patients with angina pectoris. nadolol tablets are indicated in the management of hypertension; it may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. nadolol tablets are contraindicated in bronchial asthma, sinus bradycardia and greater than first-degree conduction block, cardiogenic shock, and overt cardiac failure (see warnings).